ERBB2 and neoplasm: Consideration of tumour sample selection is important in view of the general availability of more than one tumour sample per patient, including diagnostic core biopsy, surgical excisions, treatment naïve and post-treatment tumours, nodal and distant metastases, etc. This begs the question of whether HER2-low expression is static or undergoes evolution in various stages of the disease.